Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Emory University
With
PRIMARY OBJECTIVE: I. To evaluate anti-tumor activity of the lenvatinib by assessing the overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of lenvatinib in patients with recurrent HCC after liver transplantation. II. To evaluate the anti-tumor activity of the lenvatinib by assessing progression-free survival (PFS) and overall survival (OS) and duration of response. TERTIARY/EXPLORATORY OBJECTIVE: I. To assess the effects of the lenvatinib on circulating tumor cells and biomarkers. OUTLINE: Patients receive lenvatinib orally (PO) once daily (QD). Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the protocol therapy. After completion of study treatment, patients are followed for 30 days and then every 90 days until death or 2 years from registration.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
